The companies are developing and commercializing MPC-06-ID, a phase 3 allogeneic cell therapy candidate. The companies hope the therapy can treat chronic lower back pain caused by degenerative disc disease. If successful, Grünenthal will have commercialization rights to the drug in Europe and Latin America.
More articles on biologics:
Stryker adds to spine division with $550M acquisition: 3 details
New York spine surgeon pleads guilty to illegal painkiller prescription, faces $250K fine
15 spine, neurosurgeon moves in August
